Table 7 Summary of impact of academic detailing visits on secondary outcomes

Average defined daily dose of analgesic and NSAIDs per patient reimbursed for an analgesic or NSAID per month, in intervention compared to control group (SO1)

0.0640 [− 0.1916; 0.3196]

0.1090 [− 0.1484; 0.3664]

0.2186 [− 0.0707; 0.5079]

Odds of being reimbursed for paracetamol, in intervention compared to control group (SO2)

1.0081 [0.9932;1.0232]

0.9976 [0.9811; 1.0144]

1.0289 [0.9941; 1.0649]

Odds of being reimbursed for an NSAID, in intervention compared to control group (SO3)

1.0078 [0.9943; 1.0214]

1.0055 [0.9918; 1.0194]

1.0269* [1.0033; 1.0510]

Odds of being reimbursed for both an NSAID and a PPI when reimbursed for an NSAID for the first time in 3 months, in intervention compared to control group (SO4)

1.0423 [0.9689; 1.1212]

1.0482 [0.9621; 1.1420]

1.0155 [0.9532; 1.0819]

Average defined daily dose of analgesic and NSAIDs per patient reimbursed for an analgesic or NSAID per month, in intervention compared to control group (SO1)

0.0455 [− 0.0183; 0.1094]

0.0316 [− 0.0369; 0.1001]

0.0374 [− 0.0470; 0.1218]

Odds of being reimbursed for paracetamol, in intervention compared to control group (SO2)

0.9867* [0.9766; 0.9968]

0.9889* [0.9785; 0.9994]

0.9960 [0.9871; 1.0049]

Odds of being reimbursed for an NSAID, in intervention compared to control group (SO3)

0.9907 [0.9801; 1.0015]

0.9907 [0.9809; 1.0006]

0.9998 [0.9925; 1.0072]

Odds of being reimbursed for both an NSAID and a PPI when reimbursed for an NSAID for the first time in 3 months, in intervention compared to control group (SO4)

0.9907 [0.9539; 1.0289]

0.9972 [0.9564; 1.0398]

1.0037 [0.9542; 1.0557]